|1.||Shih, C: 4 articles (12/2001 - 03/2001)|
|2.||Teicher, B A: 4 articles (12/2001 - 03/2001)|
|3.||Menon, K: 4 articles (12/2001 - 03/2001)|
|4.||Alvarez, E: 4 articles (12/2001 - 03/2001)|
|5.||Faul, M M: 3 articles (12/2001 - 05/2001)|
|6.||Galbreath, E: 3 articles (12/2001 - 03/2001)|
|7.||Menon, Krishna: 2 articles (08/2002 - 01/2002)|
|8.||Teicher, Beverly A: 2 articles (08/2002 - 01/2002)|
|9.||Shih, Chuan: 2 articles (08/2002 - 01/2002)|
|10.||Alvarez, Enrique: 2 articles (08/2002 - 01/2002)|
09/01/2001 - "The compound 317615 x 2HCl, a selective protein kinase Cbeta inhibitor, was not very cytotoxic toward human CaKi1 renal cell carcinoma cells or human HT-29 colon carcinoma cells in monolayer culture. "
05/01/2001 - "Gemcitabine produced a 15-day tumor growth delay of the HS746T gastric carcinoma that was increased to 40 days when combined simultaneously with 317615.2HCl and to 30 days with the sequential treatment regimen. "
09/01/2001 - "The HT-29 colon carcinoma angiogenesis was also responsive to 317615 x 2HCl, such that the number of intratumoral vessels stained by CD31 or CD105 was decreased to 40% to 50% of the controL 5-fluorouracil, cisplatin or fractionated radiation therapy was combined with treatment with 317615 x 2HCl in the simultaneous combination treatment regimen in animals bearing HT-29 colon carcinoma xenografts. "
08/01/2002 - "In cell culture, the compound 317615 2HCl, a potent inhibitor of VEGF-stimulated HUVEC proliferation, was not very effective against MX-1 breast cancer cells (IC50= 8.1 microM) or SKOV-3 ovarian carcinoma cells (IC50 = 9.5 microM). "
|2.||Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung)
12/01/2001 - "Treatment with 317615.2HCl was an effective therapy in the Calu-6 non-small-cell lung carcinoma xenograft when the compound was administered early (days 4-18) or later (days 14-30). "
12/01/2001 - "In cell culture, the compound 317615.2HCl, a potent inhibitor of VEGF-stimulated HUVEC proliferation, was not very effective against Calu-6 non-small-cell lung carcinoma cells (IC50 26 microM). "
|3.||Breast Neoplasms (Breast Cancer)
01/01/2002 - "317615 x 2HCl represents a new approach to antiangiogenic therapy in cancer-blocking multiple growth factor signaling pathways in endothelial cells with a single agent. "
12/01/2001 - "Administration of 317615.2HCl also increased the tumor growth delay produced by fractionated radiation therapy in the Lewis lung tumor. "
12/01/2001 - "Administration of 317615.2HCl orally twice daily to nude mice bearing subcutaneous Calu-6 tumors resulted in a decreased number of intratumoral vessels as determined by CD31 and CD105 staining to 50% of the number in control tumors. "
09/01/2001 - "The resulting tumor growth delays indicated that administration of 317615 x 2HCl increased the effects of the cytotoxic therapy. "
09/01/2001 - "CaKi1 tumor angiogenesis was very responsive to treatment with 317615 x 2HCl such that the number of intratumoral vessels stained by CD31 or CD105 was decreased to 20% of the control. "
|5.||Small Cell Lung Carcinoma (Small Cell Lung Cancer)
01/01/2002 - "In cell culture, 317615 x 2HCl was a more potent inhibitor of VEGF-stimulated HUVEC proliferation (IC50 150 nM, 72 h) than of human SW2 small-cell lung carcinoma cell proliferation (IC50 3.5 microM, 72 h). "
01/01/2002 - "The compound 317615 x 2HCl was tested in culture and in vivo in the rat corneal micropocket and in the SW2 small-cell lung carcinoma human tumor xenograft. "
|1.||Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)
|2.||K 76 carboxylic acid
|7.||Protein Kinases (Protein Kinase)
|1.||Heterologous Transplantation (Xenotransplantation)